Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

Next Previous
Trial Profile

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VSV-IFNbeta-NIS (Primary) ; Cemiplimab; Cyclophosphamide; Ipilimumab; Nivolumab; Ruxolitinib
  • Indications Acute myeloid leukaemia; Anaplastic large cell lymphoma; B-cell lymphoma; Cutaneous T-cell lymphoma; Multiple myeloma; Mycosis fungoides; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; First in man

Most Recent Events

  • 28 Mar 2024 Planned End Date changed from 1 Dec 2024 to 1 Apr 2032.
  • 28 Mar 2024 Planned primary completion date changed from 1 Dec 2024 to 31 Dec 2028.
  • 06 Feb 2024 Number of treatment arms increased from 3 to 4 by the addition of Experimental: Group D (VSV-IFNbeta-NIS, ruxolitinib, cemiplimab) arm, thus adding Cemiplimab also to the treatment regimen.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top